Search

After studying new photographs of the Mesha Stele and the squeeze of the stele prepared before the stone was broken, we dismiss Lemaire's proposal to read ('House of David') on Line 31. It is now clear that there are three consonants in the name of the monarch mentioned there, and that the first is a beth. We cautiously propose that the name on Line 31 be read as Balak, the king of Moab referred to in the Balaam story in Numbers 22–24. [ABSTRACT FROM AUTHOR]

Abstract: We report on a demonstration of loose multiphysics coupling between a basin modeling code and a seismic code running on a large parallel machine. Multiphysics coupling, which is one critical capability for a high performance computing (HPC) framework, was implemented using the MOAB open-source mesh and field database. MOAB provides for code coupling by storing mesh data and input and output field data for the coupled analysis codes and interpolating the field values between different meshes used by the coupled codes. We found it straightforward to use MOAB to couple the PBSM basin modeling code and the FWI3D seismic code on an IBM Blue Gene/P system. We describe how the coupling was implemented and present benchmarking results for up to 8 racks of Blue Gene/P with 8192 nodes and MPI processes. The coupling code is fast compared to the analysis codes and it scales well up to at least 8192 nodes, indicating that a mesh and field database is an efficient way to implement loose multiphysics coupling for large parallel machines. [Copyright &y& Elsevier]

Copyright of Archaeologischer Anzeiger is the property of Deutsches Archaologisches Institut and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

SUMMARY: Despite the considerable impact that respiratory syncytial virus (RSV) infections have in the health of children and adults, the development of therapeutic interventions has been remarkably slow. In the 1980s, advances in the characterisation of neutralising antibodies against RSV led to the development and clinical application of a polyclonal immunoglobulin preparation with high titres of neutralising antibodies against RSV (RSV IVIG). The next step was the development of neutralising monoclonal antibodies. Only palivizumab demonstrated clinical efficacy and was licensed in 1998 by the US FDA, and subsequently by the different world drug regulatory agencies. Motavizumab (MEDI-524) is a novel recombinant humanised IgG1 mAb derived from palivizumab with enhanced anti-RSV neutralising activity. In recent years, in addition to the anti-RSV antibodies, a number of alternative strategies against RSV are being developed. The most innovative approach is the use of siRNAs (small inhibitory RNAs) with specific anti-RSV activity. [Copyright &y& Elsevier]